Uncategorized

Pfizer scraps Seagen-developed ADC for solid tumors

Published

on

Just weeks after Pfizer’s Seagen-acquired antibody-drug conjugate sigvotatug vedotin failed a Phase 3 non-small cell lung cancer study, the big pharma has quietly culled another program being developed by the ADC specialist.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version